This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Agenus' (AGEN) Q1 Loss Wider than Expected, Shares Down
by Zacks Equity Research
Agenus (AGEN) incurs wider-than-expected loss in Q1 and did not report any revenues during the quarter. The company expects to file six investigational new drugs in 2018.
Perrigo (PRGO) Misses on Earnings in Q1, Reiterates View
by Zacks Equity Research
Perrigo (PRGO) misses earnings estimates but exceeds revenue expectations in Q1. The company reiterates its revenue and adjusted earnings outlook for 2018.
Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.
Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Alnylam (ALNY) incurs narrower-than-expected loss and missed revenue estimates in Q1. With several pipeline related events lined up and potential approval for patisiran, we expect investor focus to remain on the related updates.
AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View
by Zacks Equity Research
AMAG incurs wider-than-expected loss in the first quarter of 2018. The company raised 2018 revenue guidance.
Aduro (ADRO) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Aduro's (ADRO) loss in Q1 narrows from the estimate. Moreover, revenues top the same and surge substantially year over year on receipt of a milestone payment.
Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View
by Zacks Equity Research
Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.
Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1
by Zacks Equity Research
Spectrum (SPPI) reports narrower-than-expected loss in the first quarter and also beat revenues. Rolontis successful in phase III study.
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress
by Zacks Equity Research
Sarepta (SRPT) reports narrower-than-expected loss for the first quarter of 2018. However, sales miss estimates.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.
Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates
by Zacks Equity Research
Conatus (CNAT) reports in-line loss in Q1 while revenues beat estimates. Moreover, the top line improves year over year.
Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y
by Zacks Equity Research
Acorda's (ACOR) earnings and revenues lag estimates in Q1. The company reiterates its 2018 outlook for the key drug Ampyra.
Bayer (BAYRY) Misses Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Bayer (BAYRY) misses first-quarter 2018 earnings and sales estimates.
Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) disappoints with wider-than-expected loss in the first quarter. Appoints Joseph Truitt as new CEO.
What Lies Ahead for Ligand (LGND) This Earnings Season? (Revised)
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.
What Lies Ahead for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.
Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.
Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.
Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View
by Zacks Equity Research
Zoetis (ZTS) exceeds both earnings and sales expectations in the first quarter of 2018.
Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook
by Zacks Equity Research
Merck (MRK) beats estimates for earnings but misses the same for sales in Q1. Sales of Keytruda remain strong in the quarter.
Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y
by Zacks Equity Research
Allergan's (AGN) first-quarter 2018 earnings surpass estimates with revenues also marginally beating the same. Moreover, the company ups its adjusted earnings and sales view for the full year.
Ligand Pharmaceuticals Incorporated (LGND) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) Sees Hammer Chart Pattern: Time to Buy?
Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat
by Zacks Equity Research
Roche (RHHBY) beat sales estimates in the first quarter driven by strong performance of Ocrevus and Perjeta which offset the legacy sales decline.
Medicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/Y
by Zacks Equity Research
The Medicines Company (MDCO) incurs wider-than-expected loss in the first quarter of 2018. The top line also missed estimates and declined year over year.
Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Alkermes (ALKS) posts wider than expected loss in the first quarter of 2018. However, sales beat estimates.